Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Cagrilintide
Beginner tier: 250 mcg, weekly · clinical trials
Also known as: NN9838, AM833
REDEFINE 1 enrolled 3,416 adults and settled the question: amylin receptor activation produces real weight loss. Cagrilintide (NN9838) is a long-acting amylin analog dosed once per week by subcutaneous injection. At 2.4 mg, monotherapy produced 11.5% mean body weight loss at 68 weeks. Paired with semaglutide as CagriSema, that jumped to 20.4%. The mechanism is entirely separate from GLP-1 signaling. Novo Nordisk filed the CagriSema NDA in December 2025; no PDUFA date has been made public, and it is not FDA-approved as of October 2026. No standalone cagrilintide application exists; all current supply is research-grade and unregulated.
What Is Cagrilintide?
20.4% body weight gone at 68 weeks. That was the CagriSema arm of REDEFINE 1 [1], a Phase 3 trial of 3,416 adults with overweight or obesity.
Cagrilintide (NN9838) is a long-acting acylated amylin analog. It binds AMY1, AMY2, AMY3, and calcitonin receptors in the area postrema and hypothalamus. Where GLP-1 drugs suppress homeostatic hunger, cagrilintide targets hedonic hunger: food-cue reactivity, cravings, reward-driven eating. The two pathways are additive, which is why the combination outperforms either agent alone.
Fatty acid conjugation gives cagrilintide a 159 to 195 hour half-life (Enebo et al., Lancet 2021)[2]. One injection per week. Compare that to pramlintide, the only FDA-approved amylin analog, which requires three injections per day for roughly 2 to 3 kg total weight loss.
The Phase 2 dose-finding trial (Lau et al., Lancet 2021)[3] showed the 4.5 mg dose outperformed liraglutide 3.0 mg. REDEFINE 1 confirmed monotherapy at 2.4 mg produces 11.5 to 11.8% weight loss. CagriSema reaches 20.4% (intent-to-treat) and 22.7% (on-treatment estimand) at 68 weeks. In the REDEFINE 2 T2D cohort [4], CagriSema delivered 13.7% weight loss with 73.5% of patients reaching HbA1c at or below 6.5%.
Novo Nordisk filed the CagriSema NDA in December 2025. No standalone cagrilintide approval exists. All current supply is research-grade, with purity inconsistency flagged as the top community complaint.
How Cagrilintide Works
Amylin is a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells after meals. It slows gastric emptying, suppresses postprandial glucagon, and sends satiety signals to the brainstem. Cagrilintide mimics this hormone but lasts roughly 100 times longer in circulation thanks to fatty acid acylation (a C18 diacid attached to a lysine residue).
The primary targets are amylin receptors (AMY1, AMY2, AMY3) and calcitonin receptors concentrated in the area postrema. Activation there reduces hedonic hunger, the kind driven by food cues and reward pathways rather than caloric need. GLP-1 agonists suppress homeostatic hunger through hypothalamic circuits. The two mechanisms operate on parallel but distinct neurocircuitry.
That separation is why CagriSema produces supra-additive weight loss. REDEFINE 1 showed 20.4% for the combination versus 14.9% for semaglutide alone and 11.5% for cagrilintide alone [1]. The arithmetic sum would predict roughly 26%; the actual 20.4% suggests some ceiling effect on shared downstream pathways like gastric emptying inhibition.
Cagrilintide also suppresses postprandial glucagon secretion. In T2D patients (REDEFINE 2)[4], CagriSema improved HbA1c alongside weight, with 73.5% reaching the 6.5% threshold.
Cagrilintide Benefits
- Cagrilintide benefits center on amylin-pathway appetite control and a pharmacokinetic profile that makes weekly dosing possible.
- Targets hedonic hunger through amylin and calcitonin receptors in the area postrema, a mechanism GLP-1 drugs don't touch. This addresses food-cue reactivity and cravings specifically.
- 11.5 to 11.8% mean body weight loss at 68 weeks as monotherapy at 2.4 mg/week (REDEFINE 1, n=3,416)[1].
- Supra-additive combination with semaglutide; CagriSema reaches 20.4% weight loss, with 60% of participants losing 20% or more and 23% losing 30% or more.
- Once-weekly injection with a 159 to 195 hour half-life. Pramlintide, the only approved amylin analog, requires three daily injections for far less total weight loss.
- Breaks GLP-1 plateaus. Community reports consistently describe renewed appetite suppression after adding cagrilintide to an existing semaglutide or tirzepatide regimen.
- Metabolic improvements beyond weight: HbA1c, fasting glucose, and lipid panel markers improve at maintenance doses, confirmed in the REDEFINE 2 T2D cohort [4].
Cagrilintide: Science vs Community Consensus
CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg/week) achieves ~20.4% mean body weight loss at 68 weeks in adults with overweight/obesity (REDEFINE 1, NEJM 2025).
Read the evidence (key study, limitations)
Cagrilintide monotherapy achieves ~11.5–11.8% at the same timepoint. In T2D patients (REDEFINE 2), CagriSema delivers ~13.7% weight loss with 73.5% achieving HbA1c ≤6.5%. Combination is supra-additive vs. either agent alone.
REDEFINE 1 Phase 3 RCT, NEJM June 2025 (PMID 40544433); n=3416 non-diabetic adults; 68-week follow-up; 1:1:1:1 randomization (CagriSema vs cagrilintide vs semaglutide vs placebo)
CagriSema NDA submitted Dec 18, 2025; no public PDUFA date; not FDA-approved as of October 2026; no post-market pharmacovigilance; GI AEs in 72.5% of CagriSema participants; calcitonin receptor MTC signal unconfirmed in humans but mechanistically stronger than GLP-1 class; no data beyond 68 weeks; no standalone cagrilintide NDA filed
Viewed as the most promising non-GLP-1 weight mechanism for breaking GLP-1 plateaus or maximizing total weight loss.
Read the reports (what users report 4, common issues 4)
CagriSema equivalent stack is the dominant use case; monotherapy seen as a lower-priority option.
- Distinct amylin pathway targets hedonic hunger (food reward, cravings): complementary to GLP-1 homeostatic suppression
- Synergistic weight loss when combined with semaglutide; breaks GLP-1 weight-loss plateaus
- Once-weekly dosing with stable plasma levels (~7-day half-life) vs. pramlintide 3×/day
- Reduces portion size appetite and hedonic snacking independently of homeostatic hunger
- Research-chemical purity and batch inconsistency: no regulatory oversight; cited as #1 community complaint
- Severe additive GI effects when combined with GLP-1 at full dose; starting dose error (0.5 mg used instead of correct 0.25 mg)
- Calcitonin receptor / MTC theoretical risk and long-term safety unknowns
- Monotherapy-vs-CagriSema expectation gap (~11.5% vs ~20.4%) not well understood by new users
Science (REDEFINE 1 & 2) validates CagriSema combo and the 0.25 mg starting dose with controlled titration. Community has adopted CagriSema equivalent stacking but the 0.5 mg starting dose error persists widely, and GI management guidance is less structured than the trial protocol. Monotherapy is well-supported by Phase 3 data but underused in community due to lower weight loss ceiling vs. combo.
Cagrilintide Dosage Guide
Most common mistake: starting at 0.5 mg instead of 0.25 mg. The seven-day half-life means each dose stacks on the previous one during accumulation. Starting at double the validated initiation dose makes the first month of GI effects far worse than necessary.
Reconstitution math for a 5 mg vial: add 2 mL bacteriostatic water. That gives you 2,500 mcg per mL. On a U-100 insulin syringe, each IU mark equals 25 mcg. So 0.25 mg (250 mcg) is 10 IU; 0.5 mg is 20 IU; 1.0 mg is 40 IU; 1.7 mg is 68 IU; 2.4 mg is 96 IU. One 5 mg vial covers roughly the first two titration steps (about 3 mg total across 8 weeks).
Use bacteriostatic water, not acetic acid. Amylin peptides form fibrils at low pH. If the reconstituted solution looks cloudy or shows particles, discard the vial. Refrigerate at 2 to 8 degrees C, protect from light and agitation, use within 4 weeks.
If you're also running semaglutide, inject at separate anatomical sites. Separate days let you isolate which peptide is causing any GI issues.
Cycling
No scheduled off period.
Designed as continuous therapy. No cycling needed due to sustained amylin receptor responsiveness. Discontinuation leads to weight regain, so ongoing use is expected.
Cagrilintide is designed as continuous long-term therapy analogous to GLP-1 agonists. Amylin receptor responsiveness is maintained without tachyphylaxis at therapeutic doses: receptor desensitization is not a recognized mechanism of action loss. Discontinuation leads to rapid weight regain as appetite regulation reverts to baseline. The concept of "cycling" does not apply; ongoing use is the clinical and community standard.
- Weight regain of >2 kg within 4 weeks of stopping: confirms weight was amylin-receptor-dependent
- Appetite returning to pre-treatment baseline within 1–2 weeks of discontinuation
- Weight loss plateau at maintenance dose: not a cycling indication; instead, consider adding GLP-1 component (CagriSema combo)
Or use the universal Peptide Calculator for any peptide.
Cagrilintide Protocols by Goal
Expected: ~11.5–11.8% mean body weight loss at 68 weeks (REDEFINE 1 cagrilintide monotherapy arm)
Monitor: Monthly weight. Track GI symptoms during titration steps. Calcitonin/thyroid function at baseline if personal or family history of thyroid disease or MTC.
How to Inject Cagrilintide
- 1Reconstitute a 5 mg vial with 2 mL bacteriostatic water
Insert the needle at the side of the vial and let the water run down the glass. Swirl gently; never shake. The solution should be clear and colorless.
- 2Draw your dose using a U-100 insulin syringe
At 2,500 mcg/mL concentration: 0.25 mg equals 10 units, 0.5 mg equals 20 units, 1.0 mg equals 40 units, 1.7 mg equals 68 units, 2.4 mg equals 96 units.
- 3Clean the injection site with an alcohol swab
Recommended sites: abdomen (at least 2 inches from the navel), front of the thigh, or back of the upper arm.
- 4Step 4
Pinch a fold of skin and insert a 29 to 31 gauge needle at 45 to 90 degrees. Inject slowly. Hold for 5 to 10 seconds before withdrawing.
- 5Inject once weekly, same day each week
Morning is preferred but not required.
- 6Step 6
Follow the REDEFINE titration: 0.25 mg (10 IU) weeks 1 to 4, then 0.5 mg (20 IU) weeks 5 to 8, then 1.0 mg (40 IU) weeks 9 to 12, then 1.7 mg (68 IU) weeks 13 to 16, then 2.4 mg (96 IU) from week 17 onward. Escalate only after GI side effects from the current step have settled.
- 7Step 7
If combining with semaglutide, inject at a separate anatomical site. Separate days help you identify which peptide causes any side effects.
- 8Store the reconstituted vial at 2 to 8 degrees C
Use within 4 weeks. Discard if cloudy or discolored.
Cagrilintide Stacking Protocols
Works With
CagriSema equivalent: amylin hedonic suppression + GLP-1 homeostatic suppression; supra-additive weight loss (~20.4% combo vs 14.9% semaglutide alone). Best-studied cagrilintide combination with Phase 3 clinical data.
Cagrilintide 0.25→2.4 mg/week titration + semaglutide 2.4 mg/week (REDEFINE protocol)
Off-label community stack (CagriTirze): amylin pathway + dual GLP-1/GIP; theoretically additive via distinct receptor systems. No clinical trial data; increasing community interest post-REDEFINE.
Cagrilintide 0.25→2.4 mg/week + tirzepatide at tolerated dose; extra GI caution required
Avoid
Amylin suppresses postprandial glucagon; combined with insulin or secretagogues raises hypoglycemia risk, especially at higher cagrilintide doses.
Directly antagonize cagrilintide's gastric emptying inhibition mechanism; pharmacodynamic opposition undermines therapeutic effect.
How much does Cagrilintide cost?
Typical price
$8.25 to $12.55 per mg
Middle half of 43 US prices for 10 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Pricing updated 2026-04-09
Cagrilintide Side Effects
Calcitonin receptor activation carries a theoretical medullary thyroid carcinoma (MTC) concern that warrants attention first. Cagrilintide directly binds calcitonin receptors, making the mechanistic basis for this risk stronger than the indirect C-cell stimulation seen with GLP-1 drugs. No confirmed human MTC cases have appeared in clinical trials so far. Novo Nordisk lists personal or family history of MTC and MEN2 as contraindications. Baseline serum calcitonin testing is precautionary for anyone with thyroid disease history.
GI side effects are the most common clinical issue. In REDEFINE 1 [1], 72.5% of CagriSema participants reported at least one GI adverse event versus 34.4% on placebo. Nausea tops the list. Diarrhea, vomiting, and decreased appetite follow. These effects peak during titration (weeks 1 through 16) and improve for most people at maintenance dose.
The starting-dose error matters. Community forums show a persistent pattern of users beginning at 0.5 mg instead of the REDEFINE-validated 0.25 mg initiation dose. Cagrilintide has a seven-day half-life; each weekly dose stacks on the previous one during accumulation. Starting at double the recommended dose amplifies GI burden across the first month disproportionately.
Vomiting becomes a particular concern when cagrilintide is added on top of an existing GLP-1 at full dose. Both agents slow gastric emptying. Without reducing the GLP-1 temporarily, the additive effect can trigger severe nausea and vomiting that pushes people off the protocol entirely.
Injection site reactions (redness, mild swelling, itching) occur at typical rates for subcutaneous peptides. Rotating between abdomen, thigh, and upper arm reduces recurrence.
Hypoglycemia risk rises when cagrilintide is combined with insulin or sulfonylureas. Amylin suppresses postprandial glucagon; layering that on top of exogenous insulin can push blood glucose dangerously low. Blood glucose monitoring is recommended for anyone on concurrent diabetes medications.
Oral medications may absorb more slowly because cagrilintide delays gastric emptying. This matters for time-sensitive drugs like oral contraceptives and levothyroxine.
Research-grade purity is its own safety concern. No regulatory manufacturing standards apply to currently available cagrilintide. Batch inconsistency is the number one community complaint. Amylin-class peptides are amyloidogenic; incorrect reconstitution pH promotes fibril formation. Use bacteriostatic water at pH 5.5 to 6.5 and avoid acetic acid solutions.
When to stop: persistent severe GI symptoms that don't resolve with dose reduction; any signs of thyroid nodules or neck swelling (check calcitonin); confirmed or suspected pregnancy. If combining with insulin, any episode of symptomatic hypoglycemia needs immediate medical evaluation.
Common Issues & Solutions
Starting at 0.5 mg instead of 0.25 mg: the most common and consequential error; REDEFINE starts at 0.25 mg; starting at double dose during accumulation phase causes disproportionate GI burden due to the ~7-day half-life.
Adding cagrilintide to an existing GLP-1 without reducing GLP-1 dose: additive gastric emptying inhibition causes severe nausea/vomiting; reduce or hold GLP-1 escalation during cagrilintide titration initiation.
Injecting both peptides at the same site on the same day: use separate anatomical sites (e.g., abdomen vs. thigh) and separate days where possible to isolate which agent is causing GI effects.
Research-grade batch inconsistency: purity varies significantly between products; a third-party HPLC COA is the only independent check, and vials without one carry unknown purity.
Expecting CagriSema-level weight loss (~20%) from cagrilintide monotherapy: realistic monotherapy target is ~11.5–11.8% at 68 weeks; semaglutide combination is required for the headline REDEFINE outcomes.
Ask AI about this page
Ask AI for a second opinion on Cagrilintide dosing and side effects
Contraindications
- Pregnancy or breastfeeding: safety not established
- Known hypersensitivity to cagrilintide or any excipients
- Gastroparesis or severe gastrointestinal motility disorders
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Planned surgery: discontinue at least 20-24 days before elective procedures
Drug Interactions
- Insulin and sulfonylureas: increased hypoglycemia risk due to combined glucose-lowering effects
- Oral medications may have delayed absorption due to slowed gastric emptying
- Oral contraceptives: monitor efficacy as absorption timing may be altered
- Acetaminophen and other oral analgesics: delayed onset of action possible
- Semaglutide: no pharmacokinetic interaction observed; additive GI side effects possible
Product Quality
No FDA-approved standalone form exists; all available cagrilintide is research-grade with no regulatory manufacturing standards. Significant batch-to-batch purity inconsistency is the #1 community complaint. Amyloidogenic potential (amylin peptide class) requires specific reconstitution pH to avoid fibril formation; incorrect solvent can render product partially inactive or create particulate matter.
- Independent third-party HPLC purity (≥98%) plus mass spectrometry confirmation is the meaningful check: in-house self-certification is not.
- Reconstitute with bacteriostatic water (pH 5.5–6.5); avoid acetic acid solution which promotes amyloid fibril formation at lower pH.
- Refrigerate at 2–8°C; do not freeze; protect from agitation and light.
- Use within 4 weeks of reconstitution stored at 2–8°C; discard if any precipitate, cloudiness, or discoloration appears.
- Third-party COAs from independent analytical labs carry more weight than internal QC.
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Body weight | Weekly during titration (weeks 1–16); monthly at maintenance | Not listed |
| Fasting blood glucose / HbA1c | Baseline; every 3 months | FBG 70–99 mg/dL; HbA1c <5.7% (normal range) |
| Serum calcitonin | Baseline; at 6 months; if thyroid nodules or neck symptoms develop | <10 pg/mL (normal) |
| GI symptom log | Weekly during titration (weeks 1–16) | Not listed |
| Lipid panel | Baseline; 3–6 months into maintenance | Not listed |
Primary efficacy endpoint; tracks response to dose escalation steps
Amylin suppresses postprandial glucagon; increased hypoglycemia risk when combined with insulin or sulfonylureas; HbA1c confirms metabolic benefit in T2D or pre-diabetic patients
Cagrilintide directly activates calcitonin receptors: mechanistically stronger MTC signal than GLP-1 class (which acts indirectly via C-cell stimulation). No confirmed human cases; still precautionary per contraindication profile.
Dose-limiting nausea/vomiting is most common protocol failure cause; early tracking guides titration pace and identifies need to slow escalation
Weight loss typically improves lipid profile; confirms metabolic benefit alongside weight endpoints
Cagrilintide Before and After
Titration phase. Mild appetite reduction may begin. Nausea is most common during this period. Body adapts to amylin receptor activation.
Appetite suppression becomes noticeable. Early weight loss of 2-4%. GI side effects typically decrease as the body adjusts to dose escalation.
Steady weight loss continues. Phase 2 data showed ~6-9% body weight reduction at moderate doses by this point. Cravings and portion sizes decrease.
Full therapeutic dose. Monotherapy trials showed ~10.8% mean weight loss at 2.4mg. Metabolic markers improve. Weight loss rate stabilizes.
Continued maintenance of weight loss. In the REDEFINE 1 trial, cagrilintide monotherapy achieved ~11.8% weight loss at 68 weeks. Ongoing treatment is needed to sustain results.
What to Expect
Weeks 1 to 4 (0.25 mg), Titration Initiation: Plasma levels build gradually toward steady-state during the first month. Amylin receptor engagement begins at the area postrema and hypothalamus. Most people notice mild appetite reduction, particularly earlier satiety at meals. Nausea is the most common side effect at this step and is typically manageable at 0.25 mg. Injection site reactions can occur but usually resolve quickly. Don't expect visible weight change yet.
Weeks 5 to 16 (0.5 to 1.7 mg), Escalation Phase: Appetite suppression strengthens with each dose increase across this 12-week window. Weight loss of 2 to 5% is common. Cravings drop noticeably, especially hedonic eating like snacking and food-reward behavior. GI side effects tend to ease for most users by weeks 9 to 12 as tolerance builds through the multi-step escalation. Escalate each four-week step only after the current dose feels settled.
Weeks 17 to 32 (2.4 mg), Full Dose Established: Steady-state at the maximum maintenance dose. Weight loss continues at a steady pace. Metabolic markers (fasting glucose, lipids) start improving. Glucagon suppression peaks at postprandial windows. Monotherapy users may begin sensing plateau sensitivity around this phase; CagriSema users report a continued downward trajectory. GI side effects have mostly resolved.
Weeks 33 to 68 (2.4 mg maintenance), Maintenance Plateau: Monotherapy reaches 11.5 to 11.8% mean body weight loss by week 68 (REDEFINE 1). CagriSema hits 20.4%. Weight loss rate slows as the body stabilizes at a new metabolic set-point. Most users report continued satisfaction with appetite control even as the scale moves less dramatically.
Discontinuation, Weight Regain: Appetite returns to pre-treatment levels within 1 to 2 weeks of stopping. Measurable weight rebound follows within 2 to 4 weeks. The pattern mirrors GLP-1 discontinuation. Community consensus is direct: continuous use is required to sustain results. This is not a compound you cycle.
Detailed Timeline: Science vs Community
Gradual plasma accumulation toward steady-state. Amylin receptor engagement begins at area postrema and hypothalamus. Minimal weight loss expected at this stage.
Mild appetite reduction and early satiety, especially at meals. Nausea is most common: typically manageable at 0.25 mg. Most tolerate initiation dose well.
Appetite suppression strengthens progressively. Early weight loss 2–5%. GI side effects typically decrease as tolerance develops during multi-step escalation. Steady-state approached each step.
Noticeable reduction in food cravings, especially hedonic eating (snacking, food reward). Weight loss accelerates. GI side effects ease for most by weeks 9–12.
Steady-state at maximum maintenance dose. Continued weight loss and metabolic marker improvements (fasting glucose, lipids). Glucagon suppression at postprandial peak.
Consistent weekly weight loss. Cravings substantially reduced. Monotherapy users may begin to notice plateau sensitivity around this phase; CagriSema users report continued trajectory.
~11.5–11.8% mean body weight loss at 68 weeks for monotherapy; ~20.4% for CagriSema. Weight loss rate decelerates as new set-point established.
Monotherapy users report weight loss slowdown; most satisfied with appetite control maintenance. CagriSema users report continued loss through week 68.
Weight regain expected on cessation: amylin receptor activation no longer counteracting baseline appetite drive. Pattern mirrors GLP-1 discontinuation.
Significant appetite return and weight rebound reported within 2–4 weeks of stopping. Community consensus: continuous use required to sustain results.
Pharmacokinetics
Source: Phase 1b PK study (Enebo et al. Lancet 2021, PMID 33894838); t½ 159-195h (~7.3 days)
Pharmacokinetics: Active Dose Over Time
t½ = ~7 daysDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Cagrilintide Legal?
Cagrilintide has no standalone FDA approval. Novo Nordisk submitted the CagriSema combination NDA (cagrilintide 2.4 mg plus semaglutide 2.4 mg) on December 18, 2025. Novo Nordisk said FDA was expected to review the application in 2026. No PDUFA date has been made public, and CagriSema is not FDA-approved as of October 2026. If approved, only the fixed-dose combination pen would be commercially available.
All currently available cagrilintide is research-grade, manufactured without FDA or EMA oversight. Quality varies widely across research-grade products, and no compounding pharmacy framework covers this peptide yet. Third-party HPLC certificates of analysis from independent labs (not in-house testing) are the best purity verification currently available.
Cagrilintide is not a controlled substance. Neither WADA's 2026 Prohibited List nor its 2026 Monitoring Program names cagrilintide or any other amylin analog. Cagrilintide has no regulatory approval, so it may fall under section S0 (non-approved substances), which WADA prohibits in and out of competition. Athletes subject to anti-doping testing should check with their anti-doping organization before use.
This content is for informational and educational purposes only. Nothing on Peptide Schedule constitutes medical advice. Consult a licensed healthcare provider before using any research compound.
Evidence grade: Phase 3 trial (Peptide Evidence Gap, October 2026)
Who Should Consider Cagrilintide
- Adults with BMI ≥30 (or ≥27 with weight-related comorbidity)
- Individuals who have plateaued on GLP-1 therapy alone
- Adults seeking a non-GLP-1 weight loss mechanism
- Patients being considered for CagriSema combination therapy
- Adults with obesity and type 2 diabetes
Related Peptides
What Changed for Cagrilintide
Peptide Schedule Research TeamReviewed Apr 7, 20268 Citations
References
- [1]Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity: REDEFINE 1 (NEJM 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide: Phase 1b Trial (Lancet 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Once-weekly cagrilintide for weight management in people with overweight and obesity: Phase 2 Trial (Lancet 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes: REDEFINE 2 (NEJM 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Novo Nordisk company announcement, December 18, 2025: "The FDA is expected to review the CagriSema application in 2026" (opens in a new tab)Review
- Development of Cagrilintide, a Long-Acting Amylin Analogue (J Med Chem 2021) (opens in a new tab)PubMed 34288673PubMed
- Cagrilintide 2.4mg with semaglutide 2.4mg in type 2 diabetes: Phase 2 Trial (Lancet 2023) (opens in a new tab)PubMed 37364590PubMed
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity: Review (2023) (opens in a new tab)PubMed 36883831PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Cagrilintide?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 20–80. Community mentions on Reddit: Est. 20–80 threads; rapidly growing post-REDEFINE (mid-2025).
74 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.